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A b s t r a c t
Background: The Taxcor PL registry was a multicentre, phase IV open clinical trial, in which there participated 10 academic cen-
tres in Poland. Its aim was to assess the safety and effectiveness of the stent Genius TAXCOR I (Eurocor GmbH, Germany) at a dose
of 1 μg/mm2 of paclitaxel, implanted during PCI with elective or urgent indications. 
Material and methods: Patients who entered the study were a group of patients qualified for PCI, based on clinical symptoms
and provocative tests, in whom coronary angiography confirmed the presence of significant stenosis (length up to 25 mm) in the
coronary arteries. Implantation procedure, peri- and postoperative procedure were in accordance with guidelines and local practice.
The study protocol did not interfere with standard treatment for patients with a diagnosis of ischaemic heart disease. The total num-
ber of patients studied in the Taxcor PL registry is 100 people recruited in 10 centres in Poland. 
Results: Data were collected during the study on 100 PCIs (110 treated lesions). Average duration of PCI was 43 min (SD 24).
Mean diameter of the implanted stent was 3.17 mm (SD 0.36) and the average length of 20.5 mm (SD 5.82). The mean time of
hospitalization of patients enrolled in the study was 2.5 days (SD 3.4). During hospitalization, 2 patients experienced myocar-
dial infarction which was the result of side branch closure during PCI. Three patients had a haematoma at the puncture site,
which did not require surgical intervention and transfusion of blood products. During percutaneous coronary intervention also
three cases of distal dissection were reported (type B, C and D). There were no other adverse events. In one-month follow-up
one of the patients had a planned PCI procedure performed in another vessel than previously treated, which was the next sta-
ge of coronary revascularization. Similarly, in the 3-month follow-up one of the patients needed to undergo a PCI procedure on
a vessel untreated with Taxcor. In the 6-month follow-up (3-6 months) one patient died – he was hospitalized with a diagnosis
of malignant tumour and the gastrointestinal tract and operated on at the surgical ward (hemicolectomy); after 2 months of
hospitalization, he died due to multiorgan failure. Five patients had a second percutaneous coronary intervention in other ves-
sels than at the time of study enrolment. At 12-month follow-up (6-12 months) two patients had a second PCI procedure per-
formed, including one in a vessel treated at the time of enrolment. Ineffectiveness of supply target vessel (called target vessel
failure, TVF) occurred in three patients (death from coronary causes – 0, MI – 2, target vessel revascularization (TVR – PCI or
CABG) during the 12-month observation period – 1.
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Introduction
Percutaneous coronary intervention (PCI) is a routine
method of treatment used to restore normal blood flow
through the coronary arteries in patients with ischaemic
heart disease. Main factors limiting the effectiveness of
this method include restenosis and in-stent thrombosis.
Introduction of the antiproliferative drug-eluting stents
(drug-eluting stents, DES) reduced, but did not eliminate
the restenosis phenomenon. The symptoms of recurrent
stenosis or coronary artery occlusion typically occur 
6-9 months after PCI. The frequency of restenosis is 
20-50% and it depends on the number of clinical risk
factors and specific characteristics of the atherosclerotic
lesion [1]. Various substances were assessed clinically for
their ability to reduce restenosis. Only in the case of DES
has there been a reduction of the restenosis risk by over
75% in comparison to the uncoated, bare-metal stents [2].
Stents have been covered with immunosuppressive drugs
(sirolimus and its analogues, tacrolimus), cell proliferation
inhibitors (sirolimus, paclitaxel, actinomycin), anti-inflam -
matory drugs (dexamethasone), extracellular matrix
modulators (batimastat) or endothelium regenerating
drugs (17β-oestradiol). Described drugs are frequently
combined with synthetic polymers acting as reservoirs
releasing the drug over a period of several weeks or
months. The problem of in-stent thrombosis in patients
with implanted bare-metal stent (BMS) was initially
reduced by the introduction of dual antiplatelet therapy. It
returned in the form of a more frequent late in-stent
thrombosis caused by more widespread use of DES. This
phenomenon regards antiproliferative drug-eluting stents
and is probably related to slower endothelialization and
therefore to a longer period of contact between the
circulating blood and the stent uncoated by endothelium.
The first studies comparing the safety profile of BMS and
DES demonstrated a higher risk of in-stent thrombosis in
DES [3]. Since then the introduction of new technologies
of DES production and new drugs used for stent coating
have led to a better and better safety profile [4] and
a significant reduction of the frequency of in-stent
thrombosis. In view of many advantages of DES in
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Conclusions: Taxcor PL registry results showed that the stent Genius Taxcor I is safe to use and provides satisfactory results in
short- and long-term observation, in comparison with other commercially available coronary stent systems. 
Key words: paclitaxel-eluting stent, restenosis
S t r e s z c z e n i e
Wprowadzenie: Rejestr Taxcor PL był wieloośrodkowym, otwartym badaniem klinicznym fazy IV, w którym uczestniczyło 10 ośrod-
ków akademickich w Polsce. Jego celem była ocena bezpieczeństwa i skuteczności stentu Genius TAXCOR I (Eurocor GmbH, Ger-
many) uwalniającego paklitaksel w dawce 1 μg/mm2, implantowanego podczas przezskórnej angioplastyki wieńcowej (ang. percu-
taneous coronary intervention, PCI) ze wskazań planowych lub nagłych. 
Materiał i metody: Pacjenci włączani do badania stanowili grupę chorych kwalifikowanych do zabiegu PCI na podstawie dole-
gliwości klinicznych, wyników testów prowokacyjnych, u których w wykonanej angiografii tętnic wieńcowych potwierdzono obec-
ność istotnego zwężenia (długość do 25 mm) w zakresie tętnic wieńcowych. Procedura implantacji stentu i postępowanie około-
i pozabiegowe były zgodne z obowiązującymi wytycznymi oraz lokalną praktyką ośrodków. Protokół badania nie ingerował w stan-
dardy leczenia pacjentów z rozpoznaniem choroby niedokrwiennej serca. Łączna liczba pacjentów analizowanych w rejestrze Taxcor
PL wynosiła 100 osób zrekrutowanych w 10 ośrodkach w Polsce. 
Wyniki: Dane zgromadzone w trakcie badania dotyczą 100 zabiegów PCI w zakresie 110 leczonych zmian. Średni czas trwania
zabiegu PCI wyniósł 43 min (SD 24), średnia średnica implantowanych stentów wyniosła 3,17 mm (SD 0,36), a średnia długość
20,5 mm (SD 5,82). Średni czas hospitalizacji pacjentów włączonych do badania to 2,5 doby (SD 3,4). W trakcie hospitalizacji u 2 pa -
cjentów doszło do zamknięcia bocznicy podczas zabiegu PCI, czego następstwem był zawał mięśnia sercowego. U 3 pacjentów wystą-
pił krwiak w miejscu wkłucia, niewymagający interwencji chirurgicznej oraz przetoczenia preparatów krwi. W trakcie zabiegu PCI
raportowano ponadto 3 przypadki dystalnej dysekcji (typu B, C i D). Poza tym nie obserwowano innych zdarzeń niepożądanych.
W obserwacji 1-miesięcznej 1 pacjent miał wykonany planowy zabieg PCI w zakresie innego naczynia niż wcześniej leczone, będący
kolejnym etapem rewaskularyzacji wieńcowej. Podobnie w obserwacji 3-miesięcznej u 1 z chorych wynikła konieczność wykonania
zabiegu PCI na naczyniu nieleczonym implantacją stentu Taxcor. W 6-miesięcznej obserwacji (3.–6. miesiąc) zmarł 1 pacjent – był on
hospitalizowany i operowany na oddziale chirurgicznym (hemikolektomia) z rozpoznaniem złośliwego guza przewodu pokarmowe-
go i po 2 miesiącach zmarł z powodu niewydolności wielonarządowej. Pięciu pacjentów miało wykonany powtórny zabieg PCI w zakre-
sie innych naczyń niż w momencie włączenia do badania. W 12-miesięcznej obserwacji (6.–12. miesiąc) 2 pacjentów miało wykona-
ny powtórny zabieg PCI, w tym 1 w naczyniu leczonym w momencie włączenia do badania. Nieskuteczność zaopatrzenia naczynia
docelowego (ang. target vessel failure, TVF) wystąpiła u 3 pacjentów [zgon z przyczyn wieńcowych – 0, zawał serca – 2, rewaskula-
ryzacja zaopatrywanego naczynia (ponowna angioplastyka lub wszczepienie zespoleń omijających w zakresie zaopatrywanego naczy-
nia) w ciągu 12-miesięcznego okresu obserwacji – 1].
Wnioski: Wyniki rejestru Taxcor PL dowodzą, że stent Genius Taxcor I jest bezpieczny w użyciu i zapewnia uzyskanie zadowala-
jących wyników w obserwacji krótko- i długoterminowej, porównywalnych z innymi dostępnymi na rynku systemami stentów wień-
cowych.
Słowa kluczowe: stent uwalniający paklitaksel, restenoza
Robert J. Gil et al. Taxcor for prevention of restenosis
comparison to other therapeutic options in ischaemic heart
disease constant refinement of these stents seems an
important issue. It leads to an increase of safety and
efficacy of treatment and justifies efforts to find new
technologies and to test their effectiveness in clinical
studies. The use of DES has advantages over systemic drug
administration. Local action of the drug released from
a stent yields higher local concentration of the active
compound and their precise release during a requested
time. With this route of administration the systemic effect
is minimal and usually free from toxicity. Drugs released
from stents belong to the group of immunosuppressive
and cytostatic substances characterized by specific
pharmacokinesis and clinical action. 
Aim
The aim of the study was to assess the safety and
efficacy of the Genius TAXCOR I stent (Eurocor GmbH,
Germany) eluting 1 μg/mm2 of paclitaxel implanted during
elective or emergency PCI.
The procedure of stent implantation had to conform
with current clinical practice and standards of care of the
participating centre. 
Material and methods
Study plan
Taxcor PL registry was a multicentre, open-label phase
IV clinical trial. The registry was conducted in 10 university
centres in Poland. 
Collected data included information on PCI procedures
and laboratory results of the studied patients. According
to the protocol all patients were obliged to report data
regarding their health status during a telephone contact
with the attending physician (after 1, 3 and 6 months of
observation) and to return for examinations after 
12 months of observation. The study included 102 patients.
Two patients were excluded from the final analysis due to
large proportion of missing data.  
All data were collected with the use of electronic case
report forms (e-CRF) accessed online (ww.taxcor.pl). Each
investigator had a personal authentication login and
password, the connection was secured with SSL protocol
and the system met the standards required for EDC devices. 
Studied population
The study included consecutive patients meeting clinical
and angiographic criteria of the Genius TAXCOR I stent use
and qualified for percutaneous coronary intervention. The
main inclusion criterion was the presence of angina or other
obvious signs of myocardial ischaemia and patient’s eligibi -
lity for PCI or coronary artery bypass grafting (CABG).
Therefore the group included in the study consisted of
patients qualified for PCI based on the clinical symptoms
and/or results of the stress tests in whom coronary angio -
graphy confirmed the presence of significant coronary 
artery stenosis. Angiographic inclusion criteria were: de novo
stenosis or restenosis of the coronary artery with lumen
reduction over 70% (assessed according to the centre
defined protocols – visually or with the use of quantitative
coronary angiography (QCA)) and with angiographically
confirmed diameter > 2.25 mm and < 4.0 mm (appropriate
to the available stent sizes). The length of stenosis could not
exceed 25 mm; it was important to cover the whole stenosis
with a stent. In case of the need to place several stents (for
example due to edge dissection, displacement of the stent
during implantation or miscalculation of the stent length)
they had to overlap. Only two stenoses could be treated
during one PCI procedure, but they had to be located in two
different coronary arteries (left anterior descending of the
left coronary artery (LAD) or circumflex artery of the left
coronary artery (Cx) or right coronary artery (RCA)).
Before initiation of any study procedures patients
included in the study had to sign an informed consent
form. The study received approval from the Bioethical
Committee (Committee for Ethics and Supervision of
Studies on Humans and Animals of the Central Clinical
Hospital of the Ministry of Interior and Administration in
Warsaw).
A full list of the inclusion and exclusion criteria is
presented in Table 1.
Stent implantation procedure. 
Peri- and post-procedural treatment
The stent implantation procedure as well as peri- and
post-procedural treatment conformed with the current
guidelines and with the local practice of the centre. The stu -
dy protocol did not interfere with the standards of care in
patients with ischaemic heart disease.
Follow-up period and study end-points
Data were collected using an electronic CRF. According
to the protocol a telephone contact with the patient was
required after 1, 3 and 6 months of follow-up. There was
also a control visit with the attending physician after 
12 months of follow-up which included collection of data
on the incidents considered as MACE, classification of the
angina symptoms and ascertainment of compliance to
prescribed pharmacotherapy.
Study end-points
The primary end-point of the study was a target vessel
failure (TVF) defined as coronary death, myocardial
infarction (ST-segment elevation myocardial infarction
(STEMI) and non-ST-segment elevation myocardial infar -
ction (NSTEMI)) or target vessel revascularization (repeated
PCI or surgery with bypasses of the stented vessel) during
12 months of follow-up. In case of inability in assignment
of death or myocardial infarction to the treated vessel
these incidents were considered as such. 
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Inclusion criteria Exclusion criteria
Table 1. Study inclusion/exclusion criteria
Tabela 1. Kryteria włączenia lub wyłączenia z badania
• Age ≥ 18 years
• Negative result of the pregnancy test in women in the procreational 
period performed during 7 days before inclusion and the use of an 
effective contraception methods for 8 months after the procedure
• Planned treatment of maximally two de novo stenoses and/or 
restenoses (only after balloon angioplasty, in-stent restenosis is 
the exclusion criterion) in different main coronary arteries 
(LAD, RCA, Cx) or in their main branches eligible for PCI 
and stent implantation
• Vessel diameter 2.25-4.00 (by visual assessment)
• Stenosis length < 25 mm by visual assessment
• Vessel stenosis > 70% by visual assessment 
• Sign informed consent form before initiation of the study 
procedures
• Any predictable situation of antiplatelet drug administration for
less then 6 months (planned non-cardiac surgery, drug intolerance)
• The need for treatment of more than two stenoses in the same
vessel
• Total vessel occlusion
• Stenosis containing vessel bifurcation requiring implantation 
of a ramified stent (two stents)
• Calcified stenosis excluding the possibility of dilation
• Very tortuous coronary vessel excluding the possibility of stent 
introduction
• In-stent restenosis
• Intracoronary brachytherapy during previous 6 months
• Stenosis of the saphenous vein graft
• Stenosis of the internal thoracic artery bypass
• Unprotected left main coronary artery stenosis ≥ 50%
• Acute or chronic renal failure (plasma creatinine concentration 
> 2 mg%)
• Left ventricular ejection fraction (LVEF) < 35%
• Cardiogenic shock
• Acute infectious disease
• Predicted life expectancy below 1 year
• Any clinical situation which in the physician’s opinion may 
interfere with participation in the study
• Participation in another clinical trial in which end-points have not 
yet been met or which can influence the final results of the study
Secondary end-points of the study included:
• MACE (major adverse cardiac event) incidents defined as
death, myocardial infarction (STEMI, NSTEMI), target
vessel revascularization during 30 days and 12 months
of follow-up;
• 1-month and 12-month mortality;
• 1-month and 12-month coronary mortality, classified as
such in dubious cases;
• 1-month and 12-month myocardial infarction defined as
pathological ST-segment elevation with increase of 
CK-MB above the upper reference limit (STEMI) or lack
of ST-segment elevation with increase of CK-MB above
the upper reference limit (NSTEMI); at least 5-fold
increase of CK-MB above the upper reference limit was
necessary to diagnose myocardial infarction related to
CABG, and at least 2-fold increase of CK-MB above the
upper reference limit was necessary to diagnose a peri-
procedural myocardial infarction (related to PCI);
• target lesion revascularization (TLR) defined as any
revascularization of the stented vessel segment ± 5 mm
proximally or distally to the stented segment during 
1-month and 12-months follow-up;
• target vessel revascularization (TVR) defined as any
revascularization of the treated vessel during 1-month
and 12-months follow-up;
• in-stent thrombosis during 1-month (early) and 12-month
(late) follow-up defined as an acute coronary syndrome
with angiographically documented vessel occlusion
caused by thrombus located in the proximity of the
previously implanted stent or any myocardial infarction
or coronary death related to the treated vessel in case
of lack of angiographic confirmation;
• success of the studied device defined as achievement of
final stenosis diameter < 30% assessed by a physician
performing PCI;
• successful procedure defined as achievement of final
stenosis diameter < 30% without MACE related to the
treated lesion during hospitalization.
Statistical analysis
Because of the observational character of the study, no
formal study sample calculation was performed. Descriptive
statistics were presented for all analysed variables including
division into pre-defined subgroups. In the case of non-
parametric variables data were presented as numbers and
percentages. Continuous variables were presented as
mean, standard deviation, median, minimum, maximum
and the number of observations.
Results
The total number of patients analysed in the Taxcor PL
registry was 100 recruited in 10 centres in Poland. Baseline
demographic and clinical data of the studied patients are
presented in Table 2.
Percutaneous coronary interventions – 
detailed data
Analysis of the studied group demonstrated that in
90% of cases PCI involved one coronary artery with one
critical stenosis. Localization of the treated lesions is
presented in the Table 3.
Data obtained during the study include 100 PCI
procedures involving 110 atherosclerotic lesions. The mean
time of the PCI procedure was 43 min (SD 24). The mean
diameter of the implanted stent was 3.17 mm (SD 0.36)
and its mean diameter was 20.5 mm (SD 5.82).
Characteristics of the treated lesions by visual assessment
of the operator are presented in Table 4.
Ten patients received a 600 mg loading dose of
clopidogrel before the procedure, 6 patients received
a 300 mg loading dose and 56 patients were on chronic
clopidogrel treatment before the procedure and did not
require a loading dose. Mean dose of unfractionated
heparin used during percutaneous coronary intervention
was 7600 IU (SD 1900 IU).
In-hospital follow-up (during index 
hospitalization)
The mean time of hospitalization of patients included
in the study was 2.5 days (SD 3.4). Two PCI procedures
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Variable Number of lesions
Type of the treated lesion Native vessel 106
Restenosis 2
Atherosclerotic plaque Concentric 53
Eccentric 44
Calcifications None 62
Moderate 29
Severe 2
Ostial lesion No 95
Yes 10
Thrombus No 93
Yes 1
Other stenosis > 50% No 93
in the treated vessel Yes 8
Lesion length [mm] < 10 14
10-20 64
> 20 25
TIMI Before After 
the procedure the procedure
0 0 lesions 0 lesions
1 7 lesions 0 lesions
2 9 lesions 0 lesions
3 83 lesions 101 lesions
QCA – per investigator Before After 
the procedure the procedure
Lesion length [mm] 16.47 ±7.10 16.27 ±7.61
MLD of the stented 1.07 ±0.51 3.12 ±0.54
lesion [mm]
% DS 81 ±12 7 ±11
Table 4. Results of visual assessment of the treat-
ed lesions
Tabela 4. Wyniki oceny wizualnej leczonych zmian
Localization of the treated lesion Percentage 
One lesion LAD 45
RCA 19
Cx 20
other 6
Two lesions 10
Table 3. Localization of the treated lesions
Tabela 3. Umiejscowienie leczo nych zmian
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Baseline demographic data Value (percentage) 
or ± SD
Number of patients 100
Age [years] 63.8 ±8.9
Women 34 (34%)
Men 66 (66%)
History of diabetes/insulin use 27/100 (27%)/8
History of myocardial infarction 99 (50.5%)
Hypertension 83 (83%)
Current cigarette smoker 98 (20.4%)
Peripheral arterial disease 92 (7.6%)
Dyslipidaemia 86 (86%)
History of PCI 44 (44%)
History of coronary artery bypass 3 (3%)
grafting (CABG)
Baseline clinical data Value (percentage) 
or ± SD
Stable coronary artery disease 85/100 (85%)
Myocardial infarction on admission 4/100 (4%)
Left ventricular ejection fraction [%] 52.9 ±9.8%
Systolic blood pressure on admission [mmHg] 133.5 ±13.4
Diastolic blood pressure on admission [mmHg] 79.2 ±9.9
Heart rate [n/min] 67.9 ±8.8
Body mass index (BMI) [kg/m2] 28.4 ±4.5
Haemoglobin concentration on admission 13.9 ±1.3 
[mg/dl]
Platelet count on admission [n/ml] 212 596 ±60 996
Creatinine concentration on admission [μmol/l] 87.2 ±20.0 
Table 2. Demographic and clinical data of the stud-
ied patients
Tabela 2. Dane demo graficzne i kliniczne badanych
pacjentów
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during index hospitalization were complicated by a branch
occlusion with a consequent myocardial infarction. Three
patients suffered from a haematoma of the puncture site
which did not require surgery or blood transfusion. There
were 3 cases of distal dissection (type B, C and D) reported
during PCI procedures. No other adverse events were
reported (Table 5). 
Long-term follow-up of patients
During 1-month follow-up one patient underwent
repeated PCI procedure of the previously untreated vessel
(next step of coronary revascularization).
During 3 months follow-up (1st-3rd month) one patient
discontinued clopidogrel treatment due to gastro-intestinal
tract bleeding. He was admitted to the general surgery
ward, diagnosed with an abdominal tumour and qualified
for the surgical procedure – hemicolectomy. One patient
underwent repeated PCI of the previously untreated vessel.
During 6 months follow-up (3rd-6th month) 1 patient
died – he was hospitalized and underwent surgery
(hemicolectomy) on the surgical ward due to diagnosed
gastro-intestinal tumour (a malignant process was found
in histopathological examination) and died from multiorgan
failure after 2 months of hospitalization. Five patients
underwent repeated PCI of the previously untreated
vessels.
During 12 months follow-up (6th-12th month) 2 patients
underwent repeated PCI including one PCI of the previously
treated vessel (TVR). Sixteen patients discontinued
thienopyridine treatment 12 months after the procedure
as recommended. 
Data of patients included in the TAXCOR PL study in
various periods of follow-up are presented in Figure 1.
Summary of adverse events during 1-year follow-up is
presented in Table 6.
Analysis of study end-points
The primary end-point of the study defined by the
study protocol was a TVF. According to the definition this
complication occurred in 3 patients (coronary death – 0,
myocardial infarction [STEMI, NSTEMI] – 2, target vessel
revascularization [repeated PCI or surgery with bypasses
of the previously treated vessel] during 12 months follow-
up – 1).
The frequency of secondary end-points is presented in
Table 7.
Discussion
Results of the study procedure, in-hospital follow-up
and long-term follow-up of patients who underwent
implantation of the Genius Taxcor I stent show high safety
and efficacy of this method of treatment in patients with
ischaemic heart disease as demonstrated during 6-month
follow-up.
The presented results undoubtedly show that the use
of the Genius Taxcor I stent was safe in a large proportion
of patients and led to perfect long-term results of clinical
follow-up. Achievement of 98% success of the studied
device and 96% of the successful procedures is
comparable with the results of other registries on drug-
eluting stents.
Similarly, the frequency of MACE in 1-year follow-up
is comparable with that reported in other registries on
the efficacy and safety of DES [5], such as the one
presented in the study on 2633 patients with implanted
DES published in the CCI journal by Ran Kornowski’s
group, who reported a 3% frequency of death and over
4% frequency of TVR during 1-year follow-up. Frequency
of the same adverse events in the Taxcor PL registry did
Index – 1 month FU 1-3 months FU 3-6 months FU 6-12 months FU SUM
Death 0 0 1 (1908) 0 1
Bleeding 0 1 (1908) 0 0 1
Surgery 0 1 (1908) 0 0 1
Re-PCI 1 (1304) 1 (1309) 4 (1101, 1304, 1404, 1409) 2 (1303, 1404) 8
SUM 1 3 5 2 11
MACE 2 0 1 1 4
Table 6. Adverse events after 1 year follow-up (FU)
Tabela 6. Zdarzenia niepożądane w rocznej obserwacji
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Adverse events during hospitalization Number of patients
Death 0
Myocardial infarction 2 (2%)
Recurrence of angina 0
Repeated elective PCI 0
Stroke 0
Pulmonary embolism 0
Complications of the access site 3 (3%)
Bleeding (requiring blood transfusion) 0
MACE 2 (2%)
Table 5. Adverse events during index hospitaliza-
tion
Tabela 5. Zdarzenia niepożądane w trakcie pierwszej
hospitalizacji
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not exceed 2% [6]. Analysis of the frequency of in-stent
thrombosis reported in the published studies ranging
between one and several percent in 1-year follow-up [7]
shows that the studied stent is characterized by
a comparable safety profile regarding this complication.
Currently reported data on efficacy and safety of the
‘limus’ coated stents (such as everolimus) and publications
comparing the efficacy of paclitaxel with this new group
of drugs show the advantage of the ‘limus’ group
concerning mainly the reduction of major adverse events
or target vessel failure requiring repeated interventions [8].
Analysis of the obtained results demonstrates that the
frequency of end-points in which ‘limus’ stents show an
advantage over paclitaxel coated stents presented in the
Taxcor PL registry is similar to the one reported for the
everolimus coated stents. 
There are some limitations of the Taxcor PL study
including the lack of angiographic assessment of the results
by an independent core laboratory, the observational
character of the study and the lack of angiographic control
or full monitoring of the reported data.
Conclusions
The results of the Taxcor PL registry demonstrate that
the Genius Taxcor I stent is safe in use and leads to
satisfactory results in the short-term and long-term follow-
up, which is comparable to other commercially available
coronary stenting systems.
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End-point Number 
of cases
MACE During 30 days follow-up 2
During 12 months follow-up 4
Death During 30 days follow-up 0
During 12 months follow-up 1
Coronary During 30 days follow-up 0
death During 12 months follow-up 0
Myocardial During 30 days follow-up 2
infarction During 12 months follow-up 2
Target lesion During 30 days follow-up 0
revascularization (TLR) During 12 months follow-up 1
Target vessel During 30 days follow-up 0
revascularization (TVR) During 12 months follow-up 1
In-stent thrombosis During 30 days follow-up 0
During 12 months follow-up 0
Success of the studied Defined as final vessel diameter 98%
device at stenosis < 30%
Successful procedure Defined as final vessel diameter 96%
at stenosis < 30% without MACE 
related to the primary lesion 
until discharge 
Table 7. Secondary end-points – frequency
Tabela 7. Częstość występowania wtórnych punk-
tów końcowych
1 0 1
3
0 1
4 1 4
5
0 2
9495 9693 90
94
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